A study to find out whether Odronextamab is safe and well tolerated and how effective it is compared to Rituximab in combination with different types of chemotherapy in participants with follicular lymphoma
Descrizione riassuntiva dello studio
The study investigates the drug Odronextamab, referred to as the investigational product. The study focuses on patients with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma, NHL). The study is divided into Part 1 and Part 2. The aim of Part 1 of the study is to determine how safe and well tolerated the investigational product is. The aim of Part 2 of the study is to investigate the effect of Odronextamab compared to Rituximab and chemotherapy (the current standard treatment for non-Hodgkin lymphoma). Several research questions are explored in the study, including: • What side effects can the investigational product cause? • How much of the investigational product is present in the blood at different times? • Does the body produce antibodies against the investigational product (which could make the drug less effective or lead to side effects)? • The effects of the investigational product on the quality of life and daily functioning of the patients.
(BASEC)
Intervento studiato
Odronextamab is a monoclonal antibody described as bispecific because it can individually recognize and bind to 2 cell proteins (CD20 and CD3). Proteins are part of every cell in the body, working like small machines to ensure the function of the cell. CD20 is a protein found on the surface of both normal B cells and B cells that form certain cancers, such as follicular lymphoma. CD3 is a protein found on the surface of T cells. T cells and normal B cells are types of white blood cells in the body and are part of the immune system that fights infections. Odronextamab is intended to help T cells find and kill B cells, including cancer cells in follicular lymphoma.
(BASEC)
Malattie studiate
Participants must be at least 18 years old and have untreated follicular lymphoma.
(BASEC)
– Participants must be at least 18 years old – have follicular lymphoma – Participants have not received prior treatment for follicular lymphoma (BASEC)
Criteri di esclusione
– Participants with follicular lymphoma that has occurred in the brain or has spread to the brain (known as leptomeningeal involvement) or with certain cancers such as central nervous system lymphoma, high-grade follicular lymphoma (also referred to as type 3b) or with diffuse large B-cell lymphoma – Participants with uncontrolled hepatitis B, uncontrolled hepatitis C, or uncontrolled HIV infections (human immunodeficiency virus). If your blood tests positive for cytomegalovirus (CMV), you must receive treatment for that and show a negative test result on two occasions at least one week apart before you can be included in the study. – Pre-existing conditions of the brain and spinal cord, as described in the study protocol (BASEC)
Luogo dello studio
Basilea, Berna, San Gallo, Winterthur, Zurigo, Altro
(BASEC)
Baden
(BASEC)
Sponsor
ICON Clinical Research GmbH Switzerland
(BASEC)
Contatto per ulteriori informazioni sullo studio
Persona di contatto in Svizzera
Clinical Trials Administrator
+1 844-734-6643
clinicaltrials@clutterregeneron.comRegeneron Pharmaceuticals, Inc.
(BASEC)
Informazioni scientifiche
non disponibile
Nome del comitato etico approvante (per studi multicentrici solo il comitato principale)
Commissione d'etica svizzera nord-ovest/centrale EKNZ
(BASEC)
Data di approvazione del comitato etico
29.11.2023
(BASEC)
ID di studio ICTRP
non disponibile
Titolo ufficiale (approvato dal comitato etico)
Eine offene, randomisierte Phase-III-Studie zum Vergleich der Wirksamkeit und Sicherheit von Odronextamab (REGN1979), einem bispezifischen Anti-CD20 x Anti-CD3-Antikörper, gegenüber der Wahl des Prüfarztes bei zuvor unbehandelten Teilnehmern mit follikulärem Lymphom (OLYMPIA-1) (BASEC)
Titolo accademico
non disponibile
Titolo pubblico
non disponibile
Malattie studiate
non disponibile
Intervento studiato
non disponibile
Tipo di studio
non disponibile
Disegno dello studio
non disponibile
Criteri di inclusione/esclusione
non disponibile
non disponibile
Endpoint primari e secondari
non disponibile
non disponibile
Data di registrazione
non disponibile
Inclusione del primo partecipante
non disponibile
Sponsor secondari
non disponibile
Contatti aggiuntivi
non disponibile
ID secondari
non disponibile
Risultati-Dati individuali dei partecipanti
non disponibile
Ulteriori informazioni sullo studio
non disponibile
Risultati dello studio
Riepilogo dei risultati
non disponibile
Link ai risultati nel registro primario
non disponibile